STOCKS TELEGRAPH

Tag: pharmaceutical

  • Tenax Therapeutics (TENX) Stock Skyrockets Ahead of Inclusion in Russell Microcap Index

    Tenax Therapeutics (TENX) stock prices opened and closed at USD$1.90 on June 22nd, 2021. After-hours trading saw the stock surge by 21.05%, bringing it up to USD$2.30.

    Russell Microcap Index

    The company recently announced that it was set to join the Russell Microcap Index as of the culmination of the 2021 Russell indexes annual reconstitution effect, which should be in place as of the U.S markets opening on June 28th, 2021. The membership will remain in place for at least one year, pending repeated inclusion in the following year. Consequently, the membership entails automatic inclusion in relevant growth and value style indexes. Membership for its Russell indexes is determined by FTSE primarily on the basis of objective, market-cap rankings, and style attributes.

    Scope of Inclusion

    Membership into the Russell Microcap Index comes at a particularly opportune time for the company, as it continues to advance its two lead drug development programs, imatinib, and levosimendan. The programs are anticipated to progress to Phase 3 clinical trials soon. The next several months will also see the company welcome important research publications that will serve to support the company’s pioneering approach towards the treatment of Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction.

    Advantages of Inclusion

    Inclusion in the index means increased visibility of the company among institutional investors during a critical stage of the company’s development. The Russell indexes are broadly used for index funds and as benchmarks for active investment strategies by investment managers and institutional investors. There are currently almost USD$10.6 trillion worth of assets benchmarked against Russell’s US indexes, which are a part of Russell indexes, a leading global index provider.

    FTSE Russell

    FTSE Russell provides innovative benchmarking, analytics, and data solutions for a global consumer-base of investors. Russell calculate a massive number of indexes that serve to measure and benchmark markets and asset classes spanning more than 70 countries. 98% of the investable market on a global scale is covered by FTSE Russell.

    Future Outlook for TENX

    Armed with the significant achievement that will open many more doors for the company, TENX is poised to capitalize on the opportunities afforded to it. The company is keen to continue its trajectory of success and usher in further growth. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Cocrystal Pharma, Inc. (COCP) Stock Trends Higher Following Announcement of Covid-19 Treatment Potential

    Cocrystal Pharma, Inc. (COCP) stock prices stayed stable over the course of the market day on June 17th, 2021. Subsequent pre-market fluctuations have seen the stock climb by 3.85%, bringing it up to USD$1.35.

    CDI-45205

    The company announced on June 14th, 2021 that it had successfully demonstrated that its lead preclinical Covid-19 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2, as well as two of its primary variant strains. The company contracted a third party lab to conduct in vitro studies designed to evaluate the antiviral activity of CDI-45205 and its analogs in VeryE6-eGFP cells that were infected. Infected cells were affected by the Wuhan strain, the United Kingdom strain, and the South African variant.

    Scope of CDI-45205

    CDI-45205 and its analogs exhibited exceptional antiviral activity against each of the variant strains, going so far as to surpass the activity observed with the Wuhan strain. The FDA-approved Covid-19 RNA-dependent RNA polymerase inhibitor, remdesivir, and PF-00835231, a second protease inhibitor, were both reference inhibitors that the study was compared against. Results demonstrated CDI-45205’s excellent activity against the UK variant, with an EC50 of 1.9 uM, while activity against the South African variant exhibited an EC50 of 2.5 uM. As absence of a P-glycoprotein efflux, inhibitor is assumed in both cases.

    Cumulative Growth

    The company intends to continue conducting research into antiviral activity against other emerging variants, such as the up-and-coming Indian strain. The latest disclosed results add to the growing body of preclinical data findings of CDI-45205. Evidence suggests the new data implies the use of the protease inhibitor as an effective treatment of the coronavirus and its variants that have taken the world by storm for over a year now. Furthermore, company scientists continue to use COCP’s proprietary structure-based drug discovery platform technology to facilitate the investigation of broad-spectrum oral protease inhibitors and replication inhibitors for the treatment of Covid-19.

    Agreement with KSURF

    CDI-45205 was announced to have been selected by COCP on December 2020 as its lead Covid-19 development candidate. It was picked from a group of protease inhibitors that came into COCP’s possession through an exclusive license agreement with Kansas State University Research Foundation, which was announce earlier in 2020.

    Future Outlook for COCP

    With the world hurtling towards universal immunizations in the interest of a return to economic and social normalcy, COCP is primed to capitalize on the urgent demand for coronavirus treatments around the world. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Innate Pharma S.A. (IPHA) Stock Surges During After Hours Trading Ahead of Progress Update Meeting

    Innate Pharma S.A. (IPHA) stock prices were down by a marginal 1.87% as of the market closing on June 16th, 2021, bringing the price per share down to USD$3.9350. After-hours trading saw the stock rally by an impressive 10.55%, bringing it up to USD$4.40.

    Disclosure of New Data

    The company announced on June 10th, 2021 that it will present the most recent preclinical data from it’s next-gen, proprietary, multi-specific NK cell engager platform, ANKET. The presentation will be held at the Federation of Clinical Immunology Societies (FOCIS) meeting, showcasing Antibody-based NK cell Engager Therapeutics.

    FOCIS Presentation

    The presentation will see IPHA share new data from its tetra-specific ANKET molecule, which is the first NK cell engager technology to engage both NKp46 and CD16, the former of which is a tumor antigen and the latter a cytokine (IL-2 variant) in a single molecule. This newest development makes use of the advantages of harnessing NK cell effector functions against cells affected by cancer. It also facilitates the provision of the proliferation and activation The data set generated is founded on the company’s existing tri-specific NK cell engager technology. This technology has a proven track record of potent NK cell activation, cytotoxicity, and efficient management of tumor growth in preclinical models.

    Scope of ANKET

    Preclinical studies demonstrated the ability of in vitro tetra-specific ANKET to induce human NK cell proliferation, cytokine production, and cytolytic activity against cancer cells expressing the targeted antigen. Tetra-specific ANKET was also reported to have demonstrated in vivo anti-tumor efficacy in several tumor models, which allows for the regression of exiting tumors. Control of metastasis is also facilitated, with its associations with increased NK cell infiltration, and cytokine and chemokine production at the tumor site. The treatment also exhibited the pharmacodynamic effect, low systemic cytokine release, and a manageable safety profile in non-human primates.

    IPH6101

    The company’s leading ANKET asset is IPH6101, which has exhibited anti-tumor activity in preclinical models, including, but not limited to, facilitating pharmacokinetic pharmacodynamic and safety data in preliminary non-human primate studies. January 2021 saw the progression of the program into IND-enabling studies, with a recently announced research collaboration facilitating a second research program.

    Future Outlook for IPHA

    Armed with the development of their proprietary ANKET NK cell engager platform, IPHA is poised to continue its trajectory of success. The company is keen to continue working towards the commercialization and proliferation of their technology to usher in further gains. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Zosano Pharma Corp. (ZSAN) Stock Trending Undergoes Minor Volatility Despite Promising Debt Management

    Zosano Pharma Corp. (ZSAN) Stock Trending Undergoes Minor Volatility Despite Promising Debt Management

    Zosano Pharma Corp. (ZSAN) stock prices were down by 3.77% as of the market closing on June 15th, 2021, bringing the price per share down to USD$1.02 at the end of the trading day. After-hours trading saw the stock fall by another 5.54%, bringing it down to USD$0.96.

    Importance of Debt

    Debt is bad for bad companies; but for good companies, debt is a tool that they can use to help them grow. The underlying assumption is the ability to pay off lenders, without the company carries immense inherent risk. Without a guarantee of the fulfillment of their legal obligations, shareholders could lose the entirety of their investments. Even it doesn’t come to the worst-case scenario, the shoring up of balance sheets could result in a dilution of company shares with the issuance of offerings to raise capital. Ideally, a company takes on dilution in the hopes of using that capital to reinvest and usher in growth that exceeds that dilution, otherwise taking on debt could be a cheaper option.

    Solid Liquidity Position

    As of March 2021, ZSAN reported USD$1.63 million in debt, as compared to not having any debt as of the March of the prior year. This debt is offset by a solid liquidity position of USD$26.9 million, resulting in net cash reserves of USD$25.3 million.

    Debt Safety

    ZSAN’s most recent balance sheets show liabilities in the amount of USD$14.4 being due over the course of the following 12 months, with liabilities of USD$8.15 million due beyond that. In conjunction with cash reserves of USD$26.9 million, the company reported USD$243,000 worth of receivables due over the year. Resultingly, ZSAN boasts liquid assets that amount to USD$4.57 more than total liabilities.

    Course of Action

    This comfortable ratio indicates a relatively conservative balance sheet, with the elimination of debt not seeming too difficult. With the safety of its debt assured, owing to the surplus of cash over debt, the company’s future earnings will dictate what course their balance sheet takes moving forward. In the absence of significant operating revenue, investors rely on the hope of hasty commercialization of ZSAN’s new medical technology.

    Future Outlook for ZSAN

    Armed with a solid liquidity position and very manageable debt, ZSAN is poised to continue its trajectory of success. The company is keen to usher in further growth with the effective allocation of capital and debt. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.